Showing results (341-350 of 395) with videos related to
Sort By:
Pageof 40
Breast (Edinburgh, Scotland)|February 10, 2015
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?Olivia Pagani, Monica Ruggeri, Silvia Manunta, et al.Breast (Edinburgh, Scotland)|July 4, 2021
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterationsFabio Conforti, Laura Pala, Eleonora Pagan, et al.The Lancet. Oncology|December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozoleGiuseppe Viale, Anita Giobbie-Hurder, Meredith M Regan, et al.Journal of the National Cancer Institute|June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer PatientsMatteo Lambertini, Christine Campbell, José Bines, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy UpdateSibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.Lancet (London, England)|January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Marion Procter, Richard D Gelber, et al.Breast Cancer Research and Treatment|November 23, 2015
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR TrialIrene L Wapnir, Karen N Price, Stewart J Anderson, et al.Pageof 40